The global Viral Vector Development Market is worth US$ 730.7 Million as of now and is expected to reach US$ 4.1 Billion by the year 2033 at a robust CAGR of 18.7% between 2023 and 2033.
Viral vectors get created by using animal cell cultures, and in certain insect cell cultures, they are made out of viruses that naturally infect mammalian cells (including humans). Advancements in manufacturing techniques have proven to be vital regarding gene therapy methods incorporated for treating acquired or congenital disorders. Lentiviral vectors and AAV are used for ex-vivo and in-vivo gene delivery respectively.
Conventional medicine researchers have been riding on the notion that there is no cure to hereditary disorders.
Adeno-associated virus is utilized on frequent basis in the procedure of gene therapy. Several biopharmaceutical companies are into production and supply; which are aiming at striking a balance between demand and supply.
Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14415
The last two years also witnessed an influx of AAV-based vaccine to combat Covid-19. As of now, 2D planer technologies are being scaled out. As such, production of suspension AAV is showing inclination toward 3D suspension cell cultures/bioreactors.
At present, considerable progress is being witnessed regarding generation of cell lines to create constitutively expressed or inducible lentiviral vectors growing in suspension. Of late, the very first batch of the lentiviral vectors was generated through reliable producer cell lines in clinical trial setting.
Future Market Insights has walked through these facts with future perspectives in its latest market study entitled ‘Viral Vector Development Market’. Its team of analysts and consultants is there to execute with its bottom-up approach in primary, secondary, and tertiary modes of research.
“With an upsurge in incidences of cancer coupled with modern-day healthcare facilities, the global viral vector development market is expected to witness a major overhaul in the near future”, says an analyst from Future Market Insights.
Key Takeaways from Viral Vector Development Market
- North America holds a significant market share due to the US being subject to several patients going for gene therapy for treating diseases like heart disease, hemophilia, cancer, cystic fibrosis, diabetes, and AIDS. Gene therapy has actually raised the demand for plasmid DNA and the scenario is expected to continue even in the forecast period.
- Europe stands second with Germany leading from the front. Vibalogics is based out of Germany. It came into being in the year 2020 with an initial investment of US$ 150 Million.
- The Asia-Pacific is expected to grow at a substantial rate in the upcoming period with China being at the forefront. VectorBuilder is into development of gene delivery and research facility worth US$ 500 Million at Guangzhou (China).’Gene Delivery Research and Manufacturing Campus’ is expected to be built in the next 4 years. This campus would be having 30 manufacturing suites; which claim to produce cell lines, plasmids, AAV (adeno-associated virus), mRNA, and the other non-viral and viral vectors.
Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-14415
Competitive Development
- Thermo Fisher Scientific, in January 2021, completed acquisition of Groupe Novasep SAS (a viral vector manufacturing firm) with the objective of expanding the former’s service portfolio, thereby sufficing North America’s scientific viral vector market.
- CDMO, in February 2020, did expand manufacturing facility in Massachusetts (US). The organization did raise funding of US$ 150 Million to provide CDMO viral vectors all over North America.
- AGC Biologics, in May 2022, did announce that it’s adding viral vector suspension technology with capacity to manufacture and develop gene therapies at commercial-grade campus at Longmont, Colo.
- Avid Bioservices, Inc., in June 2022, did open AD/PD (analytical and process development) suites within company’s world-class, novel, viral vector development and CGMP (Current Good Manufacturing Plant) production facility. Viral vector facility’s CGMP manufacturing suites’ build-out is on the go, with certain capacities expected to come online in mid-calendar 2023.
Key Companies Covered:
- Thermo Fisher Scientific Inc
- Charles River (Cobra Biologics)
- NOVASEP
- uniQure N.V
- Waisman Biomanufacturing
- Creative Biogene
- GenScript Biotech Corporation
- Novartis AG
- Merck KGaA
- Takara Bio, Inc.
- FUJIFILM Diosynth Biotechnologies
- LONZA
- Danaher Corp. (Aldevron)
- Sirion Biotech GmbH
- AGC Biologics
What does the Report Cover?
- The research study is based on virus (lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, and retrovirus), by expression system (transient and stable), and by end-user (biotechnology companies, pharmaceutical companies, CRO (Contract Research Organization), and academic and research institutes).
- With continuous advancements in manufacturing techniques for developing clinical grade viral vectors, the global viral vector development market is expected to grow on a massive note in the forecast period.
Use promo code ->> FMITODAY to get a flat 20% discount
Key Market Segments Covered in Viral Vector Development Industry Research
Virus:
- Lentiviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral Vectors
- Retrovirus
Expression System:
- Transient
- Stable
Application:
- Gene Therapy
- Vaccines
- Cancer Therapy
- Others
End User:
- Biotechnology Companies
- Pharmaceutical Companies
- Contract Research Organization (CRO)
- Academic and Research Institutes
Have a Look at Healthcare Domain Related Research Reports:
- https://vocal.media/stories/gene-synthesis-market
- https://tweecampus.com/read-blog/28389
- https://marketresearch01.hashnode.dev/gene-synthesis-market-in-depth-analysis-growth-strategies-and-comprehensive-forecast-to-2033
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
